Erik Cruz on how emerging pharma can improve product launches

An emerging biopharma company faces unique challenges at launch and, therefore, must work hard to build a comprehensive launch roadmap that is grounded in data, incorporates the right technology tools, and accounts for the inherent uncertainty associated with launching a first product. Erik Cruz writes in Pharmaceutical Executive about how commercial leaders of emerging companies can maximize results at launch.